The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat CD30+ PTCL in Chinese participants. This study will look at the efficacy, safety, and pharmacokinetics (PK) of A+CHP as frontline treatment for newly diagnosed CD30+ PTCL.~The study will enroll approximately 52 participants. Participants will be enrolled in a single group to receive:~• Brentuximab vedotin 1.8 milligrams per kilogram (mg/kg) + Cyclophosphamide 750 milligrams per square meter (mg/m^2), Doxorubicin 50 mg/m^2 and Prednisone 100 mg~This multi-center trial will be conducted in China. The overall time to participate in this study is approximately 36 months.
This study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL.~The main aims of the study are to evaluate:~Side effect from the A+CHP~Check how much A+CHP stays in their blood over time. This will help Takeda to work out the best dose to give people in the future.~If A+CHP improves outcome of newly diagnosed CD30+ PTCL~Brentuximab vedotin will be given through vein on Day 1 of each 21-day cycle. Cyclophosphamide and doxorubicin will be given through vein. Prednisone will be given orally daily on Days 1 through 5.